NCT00957086: Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer |
|
|
| Active, not recruiting | 3 | 710 | RoW | Nimotuzumab, Placebo | National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore, Innogene Kalbiotech Pte. Ltd | Carcinoma, Squamous Cell of Head and Neck | 01/25 | 01/25 | | |
ChiCTR2300073467: PD-1 inhibitor combined with nimotuzumab and gemcitabine plus cisplatin for the first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma: a single arm, phase II clinical study |
|
|
| Recruiting | 2 | 26 | China | The first stage is the PD-1 inhibitor plus nimotuzumab and chemotherapy combination treatment, 21 days is a cycle, a total of 4-6 cycles, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion, day 0 (one day before chemotherapy); Nimotuzumab, intravenous infusion, on day 0 (one day before chemotherapy); Chemotherapy: Gemcitabine, intravenous infusion, day 1 and 8, (1,000 mg/m2), Cisplatin, intravenous infusion, day 1 (80 mg/m2). The second stage is the maintenance treatment, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion (day 1, every 3 weeks); Capecitabine (650 mg/m2, take orally, two times every day); PD-1 inhibitor and Capecitabine should be administered until the end of the study. | Dongguan People's Hospital; Dongguan People's Hospital, Biotech Pharmaceutical Co., Ltd. | nasopharyngeal carcinoma | | | | |